BRIEF published on 01/19/2026 at 07:35, 8 months 23 days ago Advicenne : Demande de mise sur le marché de Sibnayal® acceptée par la FDA FDA Advicenne ATRd Sibnayal® PDUFA
PRESS RELEASE published on 01/19/2026 at 07:30, 8 months 23 days ago Inside Information / Other news releases FDA accepts Advicenne's Marketing Authorization Application for Sibnayal® for dRTA treatment in the US, with a PDUFA decision target date of September 3rd, 2026 FDA Advicenne Sibnayal DRTA PDUFA
PRESS RELEASE published on 01/19/2026 at 07:30, 8 months 23 days ago Informations privilégiées / Autres communiqués Advicenne annonce l'acceptation de Sibnayal pour examen par la FDA aux Etats-Unis pour le traitement de l’ATRd. Date PDUFA fixée au 3 septembre 2026 FDA Advicenne ATRd Sibnayal PDUFA
BRIEF published on 01/12/2026 at 07:35, 8 months 30 days ago Renouvellement de l'AMM de Sibnayal® dans l'Union Européenne Advicenne Maladies Rénales EMA AMM Sibnayal®
BRIEF published on 01/12/2026 at 07:35, 8 months 30 days ago Renewal of the marketing authorization for Sibnayal® in the European Union Kidney Disease EMA Advicenna AMM Sibnayal®
PRESS RELEASE published on 01/12/2026 at 07:30, 8 months 30 days ago Informations privilégiées / Autres communiqués Advicenne annonce le succès du renouvellement de l’AMM de Sibnayal® dans l’Union Européenne. L'EMA a validé l'autorisation de mise sur le marché, renforçant le développement commercial de Sibnayal® Renouvellement Union Européenne Advicenne AMM Sibnayal
BRIEF published on 11/04/2025 at 11:35, 11 months 7 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
BRIEF published on 11/04/2025 at 11:35, 11 months 7 days ago Advicenne soumet Sibnayal® à la FDA américaine FDA Advicenne Sibnayal® Acidose Tubulaire Rénale Dépôt D'enregistrement
PRESS RELEASE published on 11/04/2025 at 11:30, 11 months 7 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
PRESS RELEASE published on 11/04/2025 at 11:30, 11 months 7 days ago Informations privilégiées / Autres communiqués Advicenne dépose le dossier d'enregistrement de Sibnayal® auprès de la FDA américaine pour le traitement de l'ATRd. Webconférence le 5 novembre 2025. Informations sur ADV7103 et le développement clinique FDA Advicenne Webconférence ATRd Sibnayal
Published on 10/10/2026 at 04:45, 1 day 18 hours ago Immutable Holdings and Jorge Masvidal's Gamebred Fighting Championship (FC) Enter Into Definitive Agreement for Proposed Reverse Takeover Transaction and Listing on the TSXV
Published on 10/10/2026 at 02:03, 1 day 21 hours ago BrandPilot AI Announces Closing of Previously Announced Debt Settlement
Published on 10/10/2026 at 02:00, 1 day 21 hours ago Battery X Metals Reports Estimated Driving Range Increase of Approximately 101 Kilometers Following a Single-Electric-Vehicle Performance Evaluation of Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Technology
Published on 10/09/2026 at 23:00, 2 days ago Trans Canada Gold Closes First Tranche of Non-Brokered Private Placement for Gross Proceeds of CDN $2,144,720
Published on 10/09/2026 at 22:15, 2 days ago Loop Industries to Host Second Quarter Fiscal 2027 Earnings Conference Call
Published on 10/10/2026 at 16:35, 1 day 6 hours ago New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026
Published on 10/10/2026 at 16:30, 1 day 6 hours ago ZPMC-Built Infrastructure Supports China's First Offshore Wind Project to Deploy 18 MW Turbines at Scale
Published on 10/10/2026 at 10:05, 1 day 13 hours ago ONLYOFFICE 10.0 brings AI tools, modular apps, and stronger security to its open-source office suite
Published on 10/09/2026 at 21:24, 2 days 1 hour ago Branicks Group AG: Extraordinary General Meeting does not approve all items on the agenda
Published on 10/09/2026 at 21:17, 2 days 1 hour ago EQS-Adhoc: Branicks Group AG: Agenda topic four at extraordinary general meeting rejected
Published on 10/09/2026 at 19:27, 2 days 3 hours ago Disclosure of transactions in own shares from October 1 to October 9, 2026
Published on 10/09/2026 at 19:27, 2 days 3 hours ago Déclaration hebdomadaire d'opérations effectuées du 1er au 9 octobre 2026
Published on 10/09/2026 at 17:45, 2 days 5 hours ago Déclaration des droits de vote à fin septembre 2026
